Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2

Carcinogenesis

Volumn 28, Issue 8, 2007, Pages 1665-1671

  Zang, Yu ^a   Doll, Mark A ^a   Zhao, Shuang ^a   States, Christopher J ^a   Hein, David W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; MESSENGER RNA;

ACETYLATION; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER RISK; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME METABOLISM; ENZYME SUBSTRATE; GENE EXPRESSION; GENOTYPE; HAPLOTYPE; MOLECULAR CLONING; MOLECULAR EPIDEMIOLOGY; MONKEY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ACETYLATION; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; CERCOPITHECUS AETHIOPS; COS CELLS; HAPLOTYPES; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SULFAMETHAZINE;

EID: 34548063942     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm085     Document Type: Article

References (50)

1. Hanna,P.E. (1996) Metabolic activation and detoxification of arylamines. Curr Med Chem, 3, 195-210.
2. Hein,D.W. (2002) Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507, 65-77.
3. Chen,T. et al. (2005) 4-Aminobiphenyl induces liver DNA adducts in both neonatal and adult mice but induces liver mutations only in neonatal mice. Int. J. Cancer, 117, 182-187.
4. Snyderwine,E.G. et al. (2002) Mammary gland carcinogenesis by food-derived heterocyclic amines and studies on the mechanisms of carcinogenesis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Mutat. Res., 506-507, 145-152.
5. Underwood,P.M. et al. (1997) Chronic, topical adminisization of 4-amino-biphenyl induces tissue-specific DNA adducts in mice. Toxicol Appl. Pharmacol., 144, 325-331.
6. Snyderwine,E.G. (1999) Mammary gland carcinogenesis by 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine in rats: Possible mechanisms. Cancer Lett., 143, 211-215.
7. Firozi,P.F et al. (2002) Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis, 23 301-306.
8. Probst-Hensch,N.M. et al. (2000) N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol. Biomakers Prev., 9, 619-623.
9. Williams,J.A. et al. (2000) N-acetyltranferases, sulfotransferases and heterocyclic amine activation in the breast. Pharmacogenetics, 11, 373-388.
10. Zhu,J. et al. (2003) Detection of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine-DNA adducts in normal breast tissues and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., 12, 830-837.
11. Hein,D.W. (2006) N-acetyltransferase 2 genetic polymorphism: Effects of carcinogen and haplotype on urinary bladder cancer risk Oncogene, 25, 1649-1658.
12. Boukourvala,S. et al. (2005) Arylamine N-acetyltranferases: What we learn from genes and genomes. Drug Metab. Rev., 37, 511-564.
13. Gago-Dominguez,M. et al. (2003) Permanent hair dyes and bladder cancer: Risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis, 24, 483-489.
14. Garcia-Closas,M. et al. (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: Results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, 366, 649-659.
15. Moslehi,R. et al. (2006) Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics 7, 819-829.
16. Ognjanovie,S. et al. (2006) NAT2 meat consumption and colorectal cancer incidence: An ecological study among 27 countries. Cancer Causes Control, 17, 1175-1182.
17. Ambrosone,C.B. et al. (1996) Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA, 276, 1494-1501.
18. Deitz,A.C. et al. (2000) N-Acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidemiol. Biomarkers Prev., 9, 905-910.
19. van der Hel,O.L. et al. (2003) NAT2 slow aoetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics, 13, 399-407.
20. Sillanpaa,P. et al. (2005) NAT2 slow acetylator genotype as an important modifier of breast cancer risk. Int. J. Cancer, 114 579-584.
21. Rovito,P.M.Jr.et al. (2005) Heterocyclic amines and genotype of N-acetyltranferases as risk factors for prostate cancer. Prostate Cancer Prostatic Dis., 8, 69-44.
22. Li,D. et al. (2006) Polymorphisms of cytochrome P45O1A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis, 27, 103-111.
23. Gemignani,F. et al. (2007) Development of lung cancer before the age of 50: The role of xenobiotic metabolism genes. Carcinogenesis.
24. Morton,L.M. et al. (2006) Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet. Genomics, 16, 537-545.
25. Deitz,A.C. et al. (2004) Impact of misclassification in genotype-exposure interaction studies: Example of N-acetyltranferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol. Biomarkers Prev., 13, 1543-1546.
26. Le Marchand,L. et al. (1996) Predictors of N-acetyltransferase activity: Should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? Cancer Epidemiol. Biormarkers Prev., 5, 449-455.
27. Hein,D.W. et al. (1995) Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res., 55, 3531-3536.
28. Fredand,AJ. et al. (2001) Functional characterization of human N-acetyltranferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics, 11, 207-215.
29. Bolt,H.M. et al. (2005) Re-investigation of the concordance of human NAT2 phenotypes and genotypes. Arch. Toxicol., 79, 196-200.
30. Blum,M. et al. (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl Acad. Sci. USA, 88 5237-5241.
31. Grant,D.M. et al. (1991) Monomorphic and polymorphic human arylamine N-acetyltranferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol. Pharmacol., 39, 184-191.
32. Zang,Y. et al. (2004) The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics, 14, 717-723.
33. Leff,M.A. et al. (1999) Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J. Biol. Chem., 274, 34519-34522.
34. Zuker,M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res., 31, 3406-3415.
35. Zang,Y. et al. (2007) Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2. Pharmacogenet. Genomics, 17, 37-45.
36. Liu,F. et al. (2006) Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. J. Mol. Biol., 361, 482-492.
37. Rodrigues-Lima,F. et al. (2002) 3D model of human arylamine N-acetyltransferase 2: Structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. Biochem Biophys. Res. Commun., 291, 116-123.
38. Hein,D.W. et al. (1994) Molecular genetics of human polymorphic N-acetyltransferase: Enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum. Mol. Genet., 3, 729-734.
39. Lan,E.Y. et al. (2006) Insights into the O-acetylation reaction of hydroxylated heterocyclic amines by human arylamine N-acetyltransferases: A oomputational study. Chem. Res. Toxicol., 19, 1182-1190.
40. Mushtag,A. et al. (2002) The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity. J. Biol. Chem., 277, 12175-12181.
41. Zhang,N. et al. (2006) NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity. J. Mol. Biol., 363, 188-200.
42. Sandy,J. et al. (2005) Investigation of the catalytic triad of arylamine N-acetyltranferases: Essential residues required for acetyl transfer to arylamines. Biochem. J., 390, 115-123.
43. Hickman,I. et al. (1995) Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli. Biochem Pharmacol., 50, 697-703.
44. Hein,D.W. et al. (2006) Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int. J. Cancer, 119, 1208-1211.
45. Dairou,J. et al. (2006). Insight into the structure of Mesorhizobium loti arylamine N-acetyltransferase 2 (MLNAT2): A biochemical and computational study. FEBS Iett., 580, 1780-1788.
46. Butcher, N.J. et al. (2004) Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: A mechanism for the slow acetylation phenotype and substrate-dependent down-regulation. J. Biol. Chem., 279, 22131-22137.
47. Savulescu,M.P. et al. (2005) Screening and characterizing human NAT2 variants. Methods enzymol, 400, 192-215.
48. Gross,M. et al. (1999) Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol. Biomarker Prev., 8, 683-692.
49. Cascorbi,I. et al. (1995) Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet., 57 581-592.
50. Grant,D.M. et al. (1990) Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J. Clin. Invest., 85, 968-972.